CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 272 enrolled
Drug / intervention
Ociperlimab +7 moredrug
Likely dose
Ociperlimab 900 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05014815
NCT05014815Phase 2Completed
CompareCT.gov

AdvanTIG-205: A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Previously Untreated Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

BeiGene·interventional·Posted Aug 20, 2021·Updated Sep 16, 2025

In Brief

A Phase 2 clinical trial evaluating Ociperlimab, Tislelizumab, and 6 other interventions for Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC) and 2 related conditions. Completed, enrolled 272 participants across 64 sites in 8 countries.

Detailed Summary

This study aimed to evaluate the safety and effectiveness of ociperlimab combined with tislelizumab and chemotherapy, compared to tislelizumab and chemotherapy alone, in participants with non-small cell lung cancer (NSCLC) that was locally advanced, could not be removed by surgery, or had spread to other parts of the body.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLocally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV
CountriesAustralia, Austria, China, France, Greece, South Korea, Spain, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedAug 20, 2021
Enrollment StartNov 16, 2021
Primary CompletionSep 4, 2024
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 4.9 years ago

Interventions

Ociperlimabdrug

900 mg intravenously (IV) once every 3 weeks (Q3W)

Tislelizumabdrug

200 mg IV Q3W

Carboplatindrug

Area under the concentration-time curve (AUC) of 5 or 6, administered on Day 1 of each 21-day cycle

Paclitaxeldrug

75 or 200 mg per square meter (mg/m²) of body surface area, administered on Day 1 of each 21-day cycle

Nab paclitaxeldrug

100 mg/m², administered intravenously on Days 1, 8, and 15 of each 21-day cycle

Cisplatindrug

75 mg/m², administered intravenously on Day 1 of each 21-day cycle

Pemetrexeddrug

500 mg/m² administered intravenously on Day 1 of each 21-day cycle

Placebodrug

Administered intravenously Q3W to match ociperlimab